Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease

Starting soon

Conditions studied: Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease

In brief

\- Determination of sarcopenia frequency among patients with metabolic dysfunction-associated steatotic liver disease 2- Exploring the association of sarcopenia with disease state (steatosis grade and fibrosis) among patients with metabolic dysfunction-associated steatotic liver disease

Key facts

Study ID

NCT07598916

Run by

Assiut University

People needed

120

Starts

2026-06-01

Expected to finish

2027-07-01

Last updated by the study team

2026-05-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The study is intended to include adult patients with metabolic dysfunction-associated steatotic liver disease which will be diagnosed based on imaging study plus one of the following criteria [8]:
• BMI ≥ 25 kg/m2 or waist circumference > 94 cm in men, > 80 cm in women
• Fasting serum glucose ≥ 100 mg/dL (≥ 5.6 mmol/L) or 2-hour post-load glucose level ≥ 140 mg/dL (≥ 7.8 mmol/L) or hemoglobin A1C (HbA1C) ≥ 5.7% or on specific drug treatment
• Blood pressure ≥ 130/85 mmHg or specific drug treatment
• Plasma triglycerides ≥ 150 mg/dL (≥ 1.70 mmol/L) or specific drug treatment
• Plasma high-density lipoprotein (HDL)-cholesterol < 40 mg/dL (< 1.0 mmol/L) for men and < 50 mg/dL (< 1.3 mmol/L) for women or specific drug treatment For significant steatosis grading, hepatic steatosis index (HSI) will be used (BMI, diabetes mellitus, and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio; cut-off score: >36). [9].
• For significant fibrosis staging, both liver stiffness measurement and several fibrosis scores will be used. Fibrosis scores will include NAFLD fibrosis score (BMI, age, hyperglycemia, AST/ALT ratio, albumin, and platelet count; cut-off score: ≥ 0.675) [9].

You may not qualify if…

• Age less than 18 years old or more than 65 years old
• Pregnant patients
• Chronic hepatitis C virus and/or hepatitis B virus infection
• Any alcohol consumption
• Autoimmune hepatitis
• Hepatic and/or extrahepatic neoplastic disorders
• Medication and/or substance use which may lead to hepatic steatosis and/or injury
• Eating disorders
• Comorbidities such as neuromuscular, pulmonary, and renal disorders
• Use of anabolic steroids

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.